6 Further Research

6 Further Research

6.1 Further good quality studies are needed:

  • to confirm the survival benefits, and the impact on QoL of gemcitabine as a first line treatment in comparison to commonly used 5-FU regimens.

  • to identify the value of gemcitabine as a second line treatment in pancreatic cancer.

  • to assess the cost-effectiveness of gemcitabine as a first and second line treatment in the light of any significant new effectiveness evidence.